Clinical trial

Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC.

NCT02964689

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2017-04-12

PhasePHASE1

Study timeline

Study start (actual)2017-04-12Date precision: day

Registry last updated2021-07-14

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Advanced Non-small Cell Lung Cancerunresolved

KRAS Gene Mutationunresolved

Lung Cancerunresolved

Interventions

BinimetinibDRUG · verified · RxNorm: binimetinib

PemetrexedDRUG · verified · RxNorm: pemetrexed

CisplatinDRUG · verified · RxNorm: cisplatin

Sponsors & collaborators

Swiss Cancer Institutelead sponsor

Mapped research locations

BaselSwitzerland1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02964689 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.